MXPA03000439A - Nueva forma de (r)-n-(5-metil -8-(4-metilpiperazin -1-il) -1,2,3,4-tetrahidro-2-naftil) -4-morfolinobenzamida. - Google Patents

Nueva forma de (r)-n-(5-metil -8-(4-metilpiperazin -1-il) -1,2,3,4-tetrahidro-2-naftil) -4-morfolinobenzamida.

Info

Publication number
MXPA03000439A
MXPA03000439A MXPA03000439A MXPA03000439A MXPA03000439A MX PA03000439 A MXPA03000439 A MX PA03000439A MX PA03000439 A MXPA03000439 A MX PA03000439A MX PA03000439 A MXPA03000439 A MX PA03000439A MX PA03000439 A MXPA03000439 A MX PA03000439A
Authority
MX
Mexico
Prior art keywords
methylpiperazin
tetrahydro
methyl
morpholinobenzamide
novel form
Prior art date
Application number
MXPA03000439A
Other languages
English (en)
Inventor
M Per-Olov Bergstr
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MXPA03000439A publication Critical patent/MXPA03000439A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

La invencion se refiere a combinaciones de fármacos sin interaccion seguras de un inhibidor de la 3-hidroxi-3- metilglutaril coenzima A (HMG-CoA), el cual es ácido (E) -7-[4-(4-fluorofenil) -6-isopropil-2-[metilsulfonil) amino} pirimidin-5-il] (3R,5s)-3,5- dihidroxihept -6-enoico o una sal farmacéuticamente aceptable del mismo (el Agente) y un fármaco el cual es tanto un inductor, inhibidor o un substrato de citocromo P450, en particular la isoenzima 3A4 del citocromo P450. Las combinaciones particulares son °tiles en tratar hiperlipidemia en humanos quienes están recibiendo quimioterapia inmunosupresora. Una combinacion preferida es el Agente y un fármaco de fibrado, el uso de tal combinacion para tratar hiperlipidemia en mamíferos, y medicamentos que contienen tal combinacion para uso en tales tratamientos.
MXPA03000439A 2000-07-20 2001-07-17 Nueva forma de (r)-n-(5-metil -8-(4-metilpiperazin -1-il) -1,2,3,4-tetrahidro-2-naftil) -4-morfolinobenzamida. MXPA03000439A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0002729A SE0002729D0 (sv) 2000-07-20 2000-07-20 Novel compound form
PCT/SE2001/001643 WO2002008212A1 (en) 2000-07-20 2001-07-17 Novel form of (r)-n-[5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamide

Publications (1)

Publication Number Publication Date
MXPA03000439A true MXPA03000439A (es) 2003-06-24

Family

ID=20280557

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03000439A MXPA03000439A (es) 2000-07-20 2001-07-17 Nueva forma de (r)-n-(5-metil -8-(4-metilpiperazin -1-il) -1,2,3,4-tetrahidro-2-naftil) -4-morfolinobenzamida.

Country Status (24)

Country Link
US (1) US6706710B2 (es)
EP (1) EP1305303A1 (es)
JP (1) JP2004504390A (es)
KR (1) KR20030015398A (es)
CN (1) CN1443178A (es)
AR (1) AR029588A1 (es)
AU (2) AU2001272872B2 (es)
BR (1) BR0112619A (es)
CA (1) CA2415046A1 (es)
CZ (1) CZ2003140A3 (es)
EE (1) EE200300028A (es)
HU (1) HUP0301116A3 (es)
IL (1) IL153836A0 (es)
IS (1) IS6679A (es)
MX (1) MXPA03000439A (es)
NO (1) NO20030220L (es)
NZ (1) NZ523528A (es)
PL (1) PL365112A1 (es)
RU (1) RU2002135626A (es)
SE (1) SE0002729D0 (es)
SK (1) SK732003A3 (es)
UA (1) UA72333C2 (es)
WO (1) WO2002008212A1 (es)
ZA (1) ZA200300129B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201001889A1 (ru) 2008-06-20 2011-08-30 Астразенека Аб Производные дибензотиазепина и их применение
GB201111704D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Novel compounds
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
GB201209587D0 (en) 2012-05-30 2012-07-11 Takeda Pharmaceutical Therapeutic compounds
CA2914263C (en) 2013-06-21 2021-05-18 Takeda Pharmaceutical Company Limited 1-sulfonyl piperidine derivatives as modulators of prokineticin receptors
GB201314286D0 (en) 2013-08-08 2013-09-25 Takeda Pharmaceutical Therapeutic Compounds
GB201318222D0 (en) 2013-10-15 2013-11-27 Takeda Pharmaceutical Novel compounds
GB201320905D0 (en) 2013-11-27 2014-01-08 Takeda Pharmaceutical Therapeutic compounds
TW201613864A (en) 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
GB201616839D0 (en) 2016-10-04 2016-11-16 Takeda Pharmaceutical Company Limited Therapeutic compounds
GB201619514D0 (en) 2016-11-18 2017-01-04 Takeda Pharmaceuticals Co Novel compounds
JP2021138648A (ja) 2020-03-04 2021-09-16 武田薬品工業株式会社 経口固形製剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9601110D0 (sv) * 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives
SE9900190D0 (sv) * 1999-01-22 1999-01-22 Astra Ab New compounds
SE9702799D0 (sv) 1997-07-25 1997-07-25 Astra Ab New compounds

Also Published As

Publication number Publication date
NO20030220L (no) 2003-03-14
BR0112619A (pt) 2003-07-29
NZ523528A (en) 2004-09-24
SE0002729D0 (sv) 2000-07-20
EE200300028A (et) 2004-10-15
IL153836A0 (en) 2003-07-31
NO20030220D0 (no) 2003-01-16
WO2002008212A1 (en) 2002-01-31
CZ2003140A3 (cs) 2003-06-18
CA2415046A1 (en) 2002-01-31
PL365112A1 (en) 2004-12-27
JP2004504390A (ja) 2004-02-12
IS6679A (is) 2003-01-14
SK732003A3 (en) 2003-08-05
AU2001272872B2 (en) 2005-08-25
UA72333C2 (en) 2005-02-15
AU7287201A (en) 2002-02-05
RU2002135626A (ru) 2004-07-27
EP1305303A1 (en) 2003-05-02
US20030166653A1 (en) 2003-09-04
CN1443178A (zh) 2003-09-17
HUP0301116A2 (hu) 2003-08-28
AR029588A1 (es) 2003-07-02
US6706710B2 (en) 2004-03-16
ZA200300129B (en) 2004-06-25
HUP0301116A3 (en) 2006-03-28
KR20030015398A (ko) 2003-02-20

Similar Documents

Publication Publication Date Title
AP1818A (en) Urea-compounds active as vanilloid receptor antagonists for the treatment of pain
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
PT1235826E (pt) Acrilamidas de quinuclidina
JO2371B1 (en) 4-phenyl-pyridine derivatives
BR0210122A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, método para o tratamento ou prevenção de uma doença, uso do composto ou de seu sal, e, método para preparar o mesmo
GEP20074208B (en) Substituted amides active at the cannabinoid-1 receptor
GB9104890D0 (en) Compositions
GB0112348D0 (en) Compounds
WO2003048164A3 (en) Adenosine a2a receptor antagonists
TW200606164A (en) New compounds
MXPA03000439A (es) Nueva forma de (r)-n-(5-metil -8-(4-metilpiperazin -1-il) -1,2,3,4-tetrahidro-2-naftil) -4-morfolinobenzamida.
TW200509933A (en) Therapeutic agents
TW200728300A (en) Therapeutic agents
AP2002002697A0 (en) Biciclic cyclohexylamines and their use as NMDA receptor antagonists.
AU2001290480A1 (en) Cyclized benzamide neurokinin antagonists for use in therapy
MXPA06007007A (es) Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores.
HUP0300863A2 (hu) N-(3,5-diklór-2-metoxi-fenil)-4-metoxi-3-(1-piperazinil)-benzolszulfonamid, eljárás elżállítására és a vegyületet tartalmazó gyógyszerkészítmény
MXPA05010783A (es) Derivados antimicrobianos de [3.1.0] biciclohexilfenil-oxazolidinona y analogos.
MXPA04000775A (es) Uso novedoso del 2 -[5-(4-fluorofenil) -3-piridilmetilamino-metil] -cromano y sus sales fisiologicamente aceptables.
MXPA05014143A (es) Derivados de cumarina para el tratamiento de trastornos oftalmicos.
DE602004022783D1 (de) Heterozyklische harnstoff-derivate für die behandlung von schmerzen.
ZA202200331B (en) Naltrexone formulation
HK1065305A1 (en) Substituted 4-aminocyclohexanol derivatives
WO2002076930A3 (en) Substituted diarylureas as stimulators for fas-mediated apoptosis
SE0100295D0 (sv) New compounds